Chapter 19 Analysis of Tnf-Related Apoptosis-Inducing Ligand In Vivo Through Bone Marrow Transduction and Transplantation

Methods in Enzymology

Volumn 446, Issue , 2008, Pages 315-331

  Song, Keli ^a   Mariappan, Raj ^a   Khosravi Far, Roya ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TNFSF10 PROTEIN, MOUSE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CANCER INHIBITION; CELL CULTURE; CELL ISOLATION; HISTOPATHOLOGY; HOMEOSTASIS; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; IN VIVO STUDY; INFLAMMATORY DISEASE; IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RETROVIRUS; REVIEW; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ARTICLE; GENETIC TRANSDUCTION; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; SPLEEN;

MURINAE; MUS;

ANIMALS; BONE MARROW TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; MICE; RETROVIRIDAE; SPLEEN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC;

EID: 50349093356     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(08)01619-4     Document Type: Review

References (27)

1. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 2 (1999) 155-162
2. Fulda S., Meyer E., and Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21 15 (2002) 2283-2294
3. Ghaffari S., Jagani Z., Kitidis C., Lodish H.F., and Khosravi-Far R. Cytokine and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc. Natl. Acad. Sci. USA 100 (2003) 6523-6528
4. Griffith T.S., Chin W.A., Lynch D.H., Jackson G.C., and Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161 6 (1998) 2833-2840
5. Guo B.C., and Xu Y.H. Bcl-2 over-expression and activation of protein kinase C suppress the trail-induced apoptosis in Jurkat T cells. Cell Res. 11 2 (2001) 101-106
6. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., and Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189 9 (1999) 1451-1460
7. Keogh S.A., Walczak H., Bouchier-Hayes L., and Martin S.J. Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett. 471 1 (2000) 93-98
8. Kim K., Fisher M.J., Xu S.Q., and el-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 6 2 (2000) 335-346
9. Kim Y., Suh N., Sporn M., and Reed J.C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277 25 (2002) 22320-22329
10. Kruisbeek A.M. In vitro assays for mouse lymphocyte function. In: Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., and Strober W. (Eds). Current Protocols in Immunology (1993), John Wiley & Sons Inc., New York 3.1.1-3.1.5
11. Lamothe B., and Aggarwal B.B. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60. J. Interferon Cytokine Res. 22 2 (2002) 269-279
12. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10 1 (2003) 66-75
13. Lee H.O., Herndon J.M., Barreiro R., Griffith T.S., and Ferguson T.A. TRAIL: A mechanism of tumor surveillance in an immune privileged site. J. Immunol. 169 9 (2002) 4739-4744
14. Mitsiades N., Mitsiades C.S., Poulaki V., Anderson K.C., and Treon S.P. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99 6 (2002) 2162-2171
15. Modur V., Nagarajan R., Evers B.M., and Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J. Biol. Chem. 277 49 (2002) 47928-47937
16. Munshi A., Pappas G., Honda T., McDonnell T.J., Younes A., Li Y., and Meyn R.E. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene 20 29 (2001) 3757-3765
17. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
18. Nesterov A., Lu X., Johnso M., Miller G.J., Ivashchenko Y., and Kraft A.S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem. 276 14 (2001) 10767-10774
19. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., and Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 364 6440 (1993) 806-809
20. Ravi R., and Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: Synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res. 62 6 (2002) 1583-1587
21. Smyth M.J., Takeda K., Hayakawa Y., Peschon J.J., van den Brink M.R., and Yagita H. Nature's TRAIL-On a path to cancer immunotherapy. Immunity 18 1 (2003) 1-6
22. Song K., Benhaga N., Anderson R.L., and Khosravi-Far R. Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res. 66 (2006) 6304-6311
23. Thakkar H., Chen X., Tyan F., Gim S., Robinson H., Lee C., Pandey S.K., Nwokorie C., Onwudiwe N., and Srivastava R.K. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J. Biol. Chem. 276 42 (2001) 38361-38369
24. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 2 (1999) 157-163
25. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 6 (1995) 673-682
26. Zhang X., Jin T.G., Yang H., DeWolf W.C., Khosravi-Far R., and Olumi A.F. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 64 19 (2004) 7086-7091
27. Zhang X.D., Zhang X.Y., Gray C.P., Nguyen T., and Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res. 61 19 (2001) 7339-7348